Mutations in the Epidermal Growth Factor Receptor(EGFR) Gene in Non-Small Cell Lung Carcinoma (NSCLC) and the Relation to Response of Treatment With Erlotinib
1. To establish a method for identifying the mutations in the EGFR gene in small clinical
samples from lung cancer patients.
2. In a retrospective study(n=500) relate survival to the frequency and types of mutations
in the EGFR gene in a Danish population of patients with advanced, inoperable non small
cell lung cancer (NSCLC) diagnosed prior to the introduction of treatment directed
3. In a prospective study (n=300), to identify the mutations in the EGFR gene in patients
treated with erlotinib, a tyrosine kinase inhibitor targeting the EGFR. Presence of
mutations will be related to the expression of other parts of the EGF system, to
mutations in the gene coding for K-RAS and to treatment response.
Observational Model: Case-Only, Time Perspective: Prospective
1 year after the last patient is enrolled
Peter Meldgaard, PhD MD
Aarhus University Hospital
Denmark: The Regional Committee on Biomedical Research Ethics
M-20080012 (ethics committee)